This article first appeared on GuruFocus.
Novo Nordisk (NYSE:NVO), the diabetes and obesity-treatment powerhouse, traded at $46.60 Monday, down nearly 2%, as two clinical signals pulled the investment case in opposite directions. Reuters reported that Novo stopped two ziltivekimab heart-failure trials, punching another hole in its diversification strategy. But semaglutide simultaneously opened the door to a younger obesity market.
The STEP Young trial enrolled 165 children aged 6 to under 12. After 68 weeks, 40.4% of semaglutide patients dropped below the obesity threshold, compared with zero placebo recipients, assuming full adherence. Both groups received diet and exercise support, more than 85% entered with severe obesity, and Novo found no new concerns involving growth or puberty.
Novo generated DKK33.39 billion of adjusted second-quarter operating profit from DKK78.49 billion of revenue, producing a muscular 42.5% margin. That cash machine can fund plenty of failed experiments, but ziltivekimab shows that building a second growth engine will not be easy. At $46.60, the stock sits 55.98% below its $105.85 GF Value, revealing just how much pessimism is already baked into the price. The pediatric result expands semaglutide’s scientific reach; detailed data, regulatory clearance and long-term patient persistence must now prove that it can expand the commercial opportunity.